Physician profile
Bimala Devkota
NPI 1972984599
$5,783.58
in general payments reported to CMS, 2019-2025
22 companies · $1,200 in 2025
The $1,200 reported for 2025 was more than what 84% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $383 · 2022: $1,310 · 2023: $1,761 · 2024: $1,130 · 2025: $1,200.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,091.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,090.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $1,391.25 | 2022-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Sunovion Pharmaceuticals INC. | $933.74 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $783.49 | 2022-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $599.41 | 2022-2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $336.64 | 2024-2025 | Cobenfy |
| Alkermes, INC. | $335.59 | 2022-2025 | Aristada, Lybalvi |
| Supernus Pharmaceuticals, INC. | $289.97 | 2022-2025 | Qelbree, Qelbree |
| Abbvie INC. | $285.57 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $138.38 | 2023-2024 | Uzedy, Austedo |
| Indivior INC. | $135.10 | 2022-2024 | Perseris, Sublocade |
| Corium, LLC | $93.31 | 2023-2025 | Azstarys |
| Biogen, INC. | $84.75 | 2024 | |
| Axsome Therapeutics, INC. | $67.06 | 2022-2023 | Auvelity |
| Ironshore Pharmaceuticals INC. | $54.64 | 2023 | Jornay Pm |
| Neurocrine Biosciences, INC. | $52.49 | 2022-2025 | Ingrezza |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $50.23 | 2022-2023 | Quviviq |
| Janssen Pharmaceuticals, INC | $47.54 | 2023-2024 | Invega Sustenna |
| Vanda Pharmaceuticals INC. | $31.51 | 2025 | Fanapt, Hetlioz |
| Tris Pharma INC | $23.46 | 2025 | Dyanavel Xr |
| Neos Therapeutics, Lp | $17.67 | 2023 | Adzenys Xr-Odt |
| Orexo US, INC. | $16.11 | 2025 | Zubsolv |
| Takeda Pharmaceuticals U.S.A., INC. | $15.67 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bimala Devkota listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.